By Joey Wong, Investor Research Analyst, LSN

Life Science Nation (LSN)’s first and largest event of the year, Digital RESI JPM 2022, is coming up in less than a week. With most of the major events happening around JPM going virtual, LSN has been overwhelmed by the number of registration requests that we have been receiving, as we do our best to ensure that every investor is a direct, active investor who looks at the early-stage life science and healthcare space. With 300+ investors confirmed to attend, including large pharma/medtech, family offices, corporate venture capitals funds, and more, this digital conference is a great opportunity to kick off your fundraising campaign and start a dialog with potential investors and strategic partners in 2022. Register now to meet with these investors:

The firm is the corporate venture arm of a senior living communities with in multiple locations and a seniors members club . The firm invests strategically in companies that can enhance their services or the elderly population quality of life in general, including in healthcare. Within healthcare, the firm is willing to invest in digital health, medical devices and diagnostic/monitoring technologies, but will not invest in therapeutics. The firm generally invests in seed to series A, and will occasionally act as a company builder, co-founding a company around a promising technology. In an initial investment, the firm will generally invest no more than $.5M, but has the ability to invest in follow-on rounds. As a strategic investor, in addition to capital, the firm can employ their facilities for pilot programs, and will occasionally do so before investing. The firm is primarily interested in Israeli companies, but will invest globally.

The firm invests in multiple sectors related to the elderly population quality of life. These technologies can include medical devices, diagnostics and digital health technologies. Examples include chronic disease management software or monitoring devices.

The firm is a strategic and active investor, and will generally take a board seat after investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is a venture capital investment firm founded in 2018 and is based in Germany. The firm is actively seeking medtech investment opportunities from Seed to Series B financing rounds, though the firm’s sweet spot is leading Series A investments. Initial check sizes can largely vary; the firm can invest anywhere from €1-5M, and seeks to invest €5-8M over the life of investment. With the current fund, the firm manages 5 portfolio companies, and seeks to invest in ~12 companies, for which the firm estimates 2/3 will be Europe/Israel-based companies, and 1/3 will be USA-based companies. Currently, the firm is not evaluating opportunities outside of USA, Europe, and Israel.

The firm is focused on investing in innovative medical devices that address cardiovascular or neurovascular disease. The firm does not invest in other sectors such as therapeutics, diagnostics, or digital health. Within medical devices, the firm is open to both pre-clinical (prototype) and clinical technologies. The firm has primarily evaluated PMA devices but is open to 510k regulatory pathways. The firm may consider other types of devices on a highly selective basis, but even such opportunities must have some connection or relevance to cardiovascular disease.

The firm prefers to lead investment rounds and seek board representation, though the firm can also co-invest alongside syndicates. Through the firm’s relationship with a proprietary commercialization and distribution platform, the firm is uniquely positioned to create value for their portfolio companies in the European market. Through this sister company relationship, the firm has access to a wide network including over 200 European hospitals, clinical sites, physicians, KOLs, etc. and can provide strategic advice on market strategy (EU clinical trials, regulatory process, reimbursement).

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The firm, headquartered in Mountain View, CA, is a multinational healthcare technology company which develops, manufactures, and sells solutions to support the vision of a fully autonomous pharmacy. The company is focused on transforming the pharmacy care delivery model and executing on the vision of the autonomous pharmacy by delivering automation, intelligence, and advanced services, powered by a single, cloud-based platform. The firm offers medication management automation solutions and adherence tools which empower healthcare systems and pharmacies to focus on clinical care rather than administrative tasks.

The firm is looking for global strategic partnerships with companies from their formation to commercialization. The company considers a variety of engagement models including acquisitions, collaborations and strategic investments when partnering with companies aligned with the company’s core business and new areas of strategic interest.
The firm is looking for global strategic partnerships with companies from their formation to commercialization. The company considers a variety of engagement models including acquisitions, research collaborations and strategic investments when partnering with companies aligned with the firm’s core business and new areas of strategic interest.

The firm is looking for strategic partnerships with early-stage companies in the medical device and digital health sectors. The company is open to subsector and indication as it relates to the company’s core business interest. The firm is open to pre-prototype companies and will consider class 1 and 2 medical device technologies.

The firm is open to all types of management teams with technologies relating to their focus and who have an interest in a strategic partnership.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Founded in 1960 the company is an international corporation that manufactures research tools and scientific instrumentation. Within the life sciences, the firm’s main focus is on instrumentation for research, including spatial biology, -omics platforms, and single cell analysis. The company has multiple partnership models including: investing, co-development, and acquisition. The firm is willing to partner globally, and prefers companies that have a pilot proof-of-concept with a potential client and a plan for early revenue before partnering with them.

Within instrumentation, the company partners with companies that are a strategic fit for the firm. The areas of interest include: spatial biology, microfluidic devices, -omics platforms, single cell analysis, and analytics. The firm’s main focus is on tools that are primarily for research use only, but will consider clinical diagnostics as well, especially when they are platform technologies with applications for both research and the clinic.

The company has no specific management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The family office has offices in Belgium and Luxembourg. The firm makes equity investments in life science companies, typically at the Series A stage or later; the firm allocates a total of EUR 3-15 million over the life of an investment. The majority of the firm’s investments are in Europe (~75%) and the rest are in the US.

In the life science sector, the firm invests in medical applications (therapeutics, diagnostics, and medical devices), digital health, life science services and tools, and agtech / food tech. For therapeutics companies, the firm only invests in companies with assets that have obtained data from in-human clinical trials (at minimum, human safety data is required). For medtech or diagnostic companies, the product must be no more than 1 year from commercialization. For digital health companies, the firm prefers to see companies that have market traction, with 2-3M EUR in revenue. In life science tools, the firm is particularly interested in companies with technologies in the -omics space, drug design platforms, or relating to data. The firm invests broadly in the life science field, but has a specific interest in technologies at the intersection between the healthcare and food industries, including nutraceuticals and the microbiome.

The firm is a hands-on investor that prefers to take a board seat and work closely with management. The firm prefers to invest as part of a strong syndicate that includes experienced investors with whom the firm has pre-existing connections.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.